Oncolytics Biotech Aktie

Oncolytics Biotech für 0 Euro bei ZERO ordern (zzgl. Spreads)

WKN DE: A2JMW5 / ISIN: CA6823108759

<
Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch
>
<
News + Analysen
News + Adhoc
Analysen
Kursziele
>
<
Unternehmen
Termine
Profil
>
<
zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs
>
11.06.2025 13:46:32

Oncolytics Biotech Announces Appointment Of Jared Kelly As CEO

(RTTNews) - Oncolytics Biotech Inc. (ONCY), Wednesday announced the appointment of Jared Kelly as Chief Executive Officer of the company.

Most recently, he played a crucial role in orchestrating the sale of Ambrx Biopharma to Johnson & Johnson for $2 billion.

As part of the appointment, the company has awarded Kelly with an initial stock option for 2.85 million shares at C$0.57 vesting equally over three years, performance-based stock option of 1.9 million shares at C$0.57, and restricted stock units tied to certain potential transactions.

Concurrently, the clinical-stage biotechnology company stated that its lead drug, pelareorep, has achieved over 60 percent objective response rate, with survival rates higher than the control groups in metastatic pancreatic cancer trials.

In the pre-market hours, Oncolytics's stock is trading at $0.43, up 0.70 percent on the Nasdaq.

Nachrichten zu Oncolytics Biotech Inc Registered Shsmehr Nachrichten

Keine Nachrichten verfügbar.

Analysen zu Oncolytics Biotech Inc Registered Shsmehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

Oncolytics Biotech Inc Registered Shs 1,38 -2,82% Oncolytics Biotech Inc Registered Shs